8.25
+5.77%
Close of 9 Nov 2026, in DKK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About ViroGates A/S
Its shares trade on Nasdaq Copenhagen under the ticker VIRO.CO. It has been listed since 26 June 2018. In the fiscal year to 31 December 2025, it reported revenue of DKK 5.3m and a net loss of DKK 10.4m. At that date it held total assets of DKK 30.6m and shareholders' equity of DKK 19.4m.
ViroGates A/S develops and markets prognostic products for the healthcare sector. Its develops a product line suPARnostic, which measures the amount of amount of soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The plasma level of suPAR reflects immune activation and is increased in such infectious diseases as HIV-1-infection, malaria, tuberculosis, Streptococcus pneumonia bacteraemia, sepsis, pneumococcal pneumonia and bacterial and viral CNS infection. Also, high suPAR levels are associated with increased inflammation, disease progression and risk of mortality. Thus, measuring suPAR levels serves as a marker to determine chances for survival upon hospital admission, as well as for monitoring for prevention of disease progression and earlier intervention time point. suPARnostic has two versions: Quantitative Point of Care Quick Triage test, which serves for patient triage in acute care, and Quantitative ELISA Assay that aims at clinical routine use.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 26 Jun 2018
- Employees
- 28
- Website
- virogates.com ↗
Leadership
Pay as last reported
- Mr. Patrik DahlenNon-Executive Chairman of the Board
- Mr. Jakob KnudsenChief Executive OfficerDKK 1.7m
- Ms. Josephine JorgensenChief Financial Officer
- Mr. Jesper Eugen-OlsenChief Scientific Officer
- Mr. Thomas KrarupVice President Global Sales & Marketing
- Mr. Lars KongsbakDirector, since 2015DKK 150,000
- Ms. Valerie SoulierIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- ViroGates A/S develops suPARnostic for immune activation monitoring in infectious diseases.
- suPARnostic offers two versions: Point of Care Quick Triage and ELISA Assay for clinical use.
- The company focuses on healthcare sector with 28 employees and listed since 2018.
Weaknesses
- ViroGates A/S has only 28 employees, limiting scalability in the healthcare market.
- The company is based in Birkeroed, DK, which may restrict access to major healthcare hubs.
- ViroGates A/S has been listed since 2018, indicating limited recent market expansion.
Opportunities
- suPARnostic can be applied in HIV-1, malaria, and tuberculosis for early intervention.
- The healthcare sector in DK shows growth potential for immune activation markers.
- Expanding suPARnostic to sepsis and bacterial CNS infections offers new markets.
Threats
- High suPAR levels are linked to increased mortality risk in infectious diseases.
- Competition in healthcare diagnostics may challenge ViroGates A/S market position.
- Regulatory changes in the Health Care industry could affect product approvals.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.